Patent application number | Description | Published |
20090203892 | Retrotransposon Inhibition in Therapy - RNA interference is useful in the treatment of cancerous lesions, wherein the RNA recognises a portion of at least one LINE-I repeat element. | 08-13-2009 |
20090232837 | ANTI TUMORAL IMMUNOGENIC PEPTIDES AND VACCINE THEREOF - The invention relates to novel, Frizzled-like, immunogenic peptides, useful for the stimulation of an immune response against various cancer types, particularly colon rectal carcinoma. | 09-17-2009 |
20090270594 | USE OF THYMOSIN ALPHA 1 FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ALLERGIES - The invention concerns the use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of allergies | 10-29-2009 |
20100004174 | USE OF THYMOSIN ALPHA 1 FOR THE PREPARATION OF A MEDICAMENT FOR THE PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES - The invention concerns the use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases such as multiple sclerosis, and inflammatory bowel diseases such as Crohn's disease or ulcerative colitis. | 01-07-2010 |
20110237577 | BICYCLIC PEPTIDOMIMETIC INHIBITORS OF ASPARTYL-PROTEASES FOR THE TREATMENT OF INFECTIOUS DISEASES - The present invention refers to 3-aza-bicyclo[3.2.1]octane derivatives of general formula (I) their preparation, use and pharmaceutical compositions useful in the treatment of pathologies associated with microbial pathogens expressing aspartyl-protease activity. | 09-29-2011 |
20110305774 | TREATMENT OF RETROVIRAL RESERVOIRS EXPLOITING OXIDATIVE STRESS - Activation of HIV-1 replication causes oxidative stress, which in turn potentiates HIV-1 replication. The common basis for the compounds of the present invention is: A) the capacity of reactivating HIV-1 from latency, and B) the ability to counteract the cellular machinery which activates in order to limit the effects of oxidative stress. In this way, oxidative stress can be potentiated and a “chain reaction” is sparked. This “chain reaction” induces a more efficient reactivation of HIV-1 from latency and, in some cases, induces selective killing of the infected cells. Actions A) and B) can either be carried out by one drug exerting both effects, or obtained by the combined use of distinct drugs. There are two main cellular machineries counteracting oxidative stress, i.e. the thioredoxin (Trx) thioredoxin reductase (TrxR) system and glutathione. Herein, we present drug strategies capable of exerting action B) by blocking either of the two machineries. | 12-15-2011 |
20120165248 | Glutathione Derivatives and Their Uses for the Treatment of Viral Diseases - Glutathione derivatives (GSH) of formula I are provided, wherein R is a thiol protection group. The derivatives are useful for the treatment of infections from Paramyxovirus, Orthomyxovirus, Herpes Simplex Virus and Acquired Immunodeficiency Syndrome Virus. | 06-28-2012 |
20140356459 | MICRORNAS AND USES THEREOF - The invention relates to molecular targets and their use to counteract tumors. Naturally occurring microRNAs that regulate human oncogenes and methods of use thereof are described. Suitable nucleic acids for use in the methods and compositions described herein include, but are not limited to, pri-miRNA, pre-miRNA, mature miRNA or fragments of variants thereof that retain the biological activity of the mature miRNA and DNA encoding a pri-miRNA, pre-miRNA, mature miRNA, fragments or variants thereof, or regulatory elements of the miRNA. The here claimed approach is efficacious also on Cancer Stem Cells. | 12-04-2014 |
Patent application number | Description | Published |
20090155260 | USE OF THYMOSIN ALPHA 1 FOR THE TREATMENT OF IMMUNOLOGICAL DISEASES - It is described the use of thymosin alpha 1 for preparing a medicament useful for the prevention or treatment of graft-versus-host disease or graft rejection reactions in organ transplantation, in a mammal subject, in which the cells, tissues or organs for transplant is selected from the group comprising: stem cells, hematopoietic stem cells, bone marrow, heart, liver, kidney, lung, pancreas, small intestine, cornea or skin. | 06-18-2009 |
20090275508 | USE OF THYMOSIN ALPHA 1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION - It is described the use of thymosin alpha 1 in combination with long pentraxin PTX3 or Ganciclovir, for the preparation of a medicament for the prevention or treatment of viral diseases and/or for inhibiting virus activation. | 11-05-2009 |
20110123499 | CELLULAR DIFFERENTIATION PROMOTION - Neural precursor cells can be encouraged to form mature neural cells twice as quickly in the absence, or reduced expression of, thymosin β4. | 05-26-2011 |
20120295840 | TREATMENT OF ASPERGILLUS INFECTIONS WITH ALPHA THYMOSIN PEPTIDES - A method for treating a human infected with | 11-22-2012 |